DDInter1731 DDInter1763
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Sunitinib {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Temsirolimus
Sunitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Sunitinib {u} (Compound) upregulates {v} (Gene) KIAA0355
KIAA0355 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Sunitinib {u} (Compound) binds {v} (Gene) FGFR2
FGFR2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Sunitinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Protein Kinase Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Temsirolimus
Sunitinib {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Sunitinib {u} (Compound) upregulates {v} (Gene) HMGCS1
HMGCS1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Sunitinib {u} (Compound) binds {v} (Gene) RPS6KA1
RPS6KA1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Sunitinib {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Febrile neutropenia {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Sunitinib {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Sunitinib (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is treated by Temsirolimus (Compound)
Sunitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Sunitinib (Compound) upregulates KIAA0355 (Gene) and KIAA0355 (Gene) is upregulated by Temsirolimus (Compound)
Sunitinib (Compound) binds FGFR2 (Gene) and FGFR2 (Gene) is upregulated by Temsirolimus (Compound)
Sunitinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class) and Protein Kinase Inhibitors (Pharmacologic Class) includes Temsirolimus (Compound)
Sunitinib (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is downregulated by Temsirolimus (Compound)
Sunitinib (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is downregulated by Temsirolimus (Compound)
Sunitinib (Compound) binds RPS6KA1 (Gene) and RPS6KA1 (Gene) is downregulated by Temsirolimus (Compound)
Sunitinib (Compound) causes Febrile neutropenia (Side Effect) and Febrile neutropenia (Side Effect) is caused by Temsirolimus (Compound)
Sunitinib (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is treated by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)